Search Results - "Salud, A."

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial by Fernandez-Martos, C., Garcia-Albeniz, X., Pericay, C., Maurel, J., Aparicio, J., Montagut, C., Safont, M.J., Salud, A., Vera, R., Massuti, B., Escudero, P., Alonso, V., Bosch, C., Martin, M., Minsky, B.D.

“…The primary results of our phase II randomized trial suggested that compared with conventional preoperative chemoradiation (CRT), the addition of chemotherapy…”
Get full text

MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial by Patel, U.B., Brown, G., Machado, I., Santos-Cores, J., Pericay, C., Ballesteros, E., Salud, A., Isabel-Gil, M., Montagut, C., Maurel, J., Ramón-Ayuso, J., Martin, N., Estevan, R., Fernandez-Martos, C.

“…Primary chemotherapy has been tested as a possible approach for patients with high risk features but predicted clear mesorectal margins on preoperative MRI…”
Get full text

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial by Rivera, Fernando, Romero, C., Jimenez-Fonseca, P., Izquierdo-Manuel, M., Salud, A., Martínez, E., Jorge, M., Arrazubi, V., Méndez, J. C., García-Alfonso, P., Reboredo, M., Barriuso, J., Muñoz-Unceta, N., Jimeno, R., López, C.

“…Purpose The phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric cancer…”
Get full text

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients by Toledano-Fonseca, M., Gómez-España, M.A., Élez, E., Grávalos, C., García-Alfonso, P., Rodríguez, R., Losa, F., Alés Díaz, I., Graña, B., Valladares-Ayerbes, M., García-Ortiz, M.V., Polo, E., Salgado, M., Rivera, F., Safont, M.J., Salud, A., Ruiz-Casado, A., Tabernero, J.M., Riesco, M.C., Rodríguez-Ariza, A., Aranda, E.

“…The benefit of adding the antiangiogenic drug aflibercept to FOLFIRI regime in metastatic colorectal cancer (CRC) patients resistant to or progressive on an…”
Get full text

TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor by Cordoba Ortega, J.F., Salud, A., Morales, S., Veas, J., Rodriguez, A.

Get full text

High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC) by Cordoba Ortega, J.F., Salud, A., Morales, S., Veas, J., Rodriguez, A.

Get full text

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) by Carrato, A, Benavides, M, Massutí, B, Ferreiro-Monteagudo, R, García Alfonso, P, Falcó, E, Reboredo, M, Cano, T, Gallego, J, Viéitez, J M, Layos, L, Salud, A, Polo, E, Dotor, E, Durán-Ogalla, G, Rodriguez-Garrote, M, Calvo, A, Grande, E, Aranda, E

“…Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of…”
Get full text

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial by Santos, C., Azuara, D., Viéitez, J.M., Páez, D., Falcó, E., Élez, E., López-López, C., Valladares, M., Robles-Díaz, L., García-Alfonso, P., Bugés, C., Durán, G., Salud, A., Navarro, V., Capellá, G., Aranda, E., Salazar, R.

“…Several studies show the importance of accurately quantifying not only KRAS and other low-abundant mutations because benefits of anti-EGFR therapies may depend…”
Get full text

Breakthrough cancer pain: review and calls to action to improve its management by Camps Herrero, C., Batista, N., Díaz Fernández, N., Escobar Álvarez, Y., Gonzalo Gómez, A., Isla Casado, D., Salud, A., Terrasa Pons, J., Guillem Porta, V.

“…In this paper, we review the current state of breakthrough cancer pain (BTcP) management. BTcP is a heterogeneous condition and a global problem for cancer…”
Get full text

First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study by García Alfonso, P, Valladares-Ayerbes, M, Muñoz Luengo, J, Pimentel, P, Viéitez, J M, Cruz Hernandez, J J, Llanos, M, Garcia Girón, C, Salud Salvia, A, Lloansí Vila, A

Get full text

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials by Jiménez-Fonseca, P., Sastre, J., García-Alfonso, P., Gómez-España, M.A., Salud, A., Gil, S., Rivera, F., Reina, J.J., Quintero, G., Valladares-Ayerbes, M., Safont, M.J., La Casta, A., Robles-Díaz, L., García-Paredes, B., López López, R., Guillot, M., Gallego, J., Alonso-Orduña, V., Diaz-Rubio, E., Aranda, E.

“…The bCTC count is a well-established prognostic biomarker in mCRC, as well as in other tumor types. The aim of this analysis was to evaluate the…”
Get full text

Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial by Rivera, Fernando, Romero, C., Jimenez-Fonseca, P., Izquierdo-Manuel, M., Salud, A., Martínez, E., Jorge, M., Arrazubi, V., Méndez, J. C., García-Alfonso, P., Reboredo, M., Barriuso, J., Muñoz-Unceta, N., Jimeno, R., López, C.

“…Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine…”
Get full text

Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial by Pineda, Estela, Salud, A, Vila-Navarro, E, Safont, MJ, Llorente, Beatriz, Aparicio, J, Vera, R, Escudero, P, Casado, E, Bosch, C, Bohn, U, Pérez-Carrión, R, Carmona, A, Ayuso, JR, Ripollés, T, Bouzas, R, Gironella, M, García-Albéniz, X, Feliu, J, Maurel, J

“…Despite initial responsiveness, acquired resistance to both bevacizumab and chemotherapy in metastatic colorectal cancer is universal. We have recently…”
Get full text

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study by Feliu, J, Salud, A, Safont, M J, García-Girón, C, Aparicio, J, Vera, R, Serra, O, Casado, E, Jorge, M, Escudero, P, Bosch, C, Bohn, U, Pérez-Carrión, R, Carmona, A, Martínez-Marín, V, Maurel, J

“…Background: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal…”
Get full text

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer by Feliu, J, Safont, M J, Salud, A, Losa, F, García-Girón, C, Bosch, C, Escudero, P, López, R, Madroñal, C, Bolaños, M, Gil, M, Llombart, A, Castro-Carpeño, J, González-Barón, M

“…Background: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for…”
Get full text

Clinical guideline SEOM: hepatocellular carcinoma by Sastre, J., Díaz-Beveridge, R., García-Foncillas, J., Guardeño, R., López, C., Pazo, R., Rodriguez-Salas, N., Salgado, M., Salud, A., Feliu, J.

“…Hepatocellular carcinoma (HCC) represents the second leading cause of cancer-related death worldwide. Surveillance with abdominal ultrasound every 6 months…”
Get full text

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer by FELIU, J, SALUD, A, DE MON, M. A, CASADO, E, GONZALEZ-BARON, M, ESCUDERO, P, LOPEZ-GOMEZ, L, BOLANOS, M, GALAN, A, VICENT, J.-M, YUBERO, A, LOSA, F, DE CASTRO, J

“…The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the…”
Get full text

2161 The prognostic significance of radiologic and pathologic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-years update GEMCAD 0801 trial by Machado, I, Patel, U, Brown, G, Salud, A, Gil, M, Montagut, C, Busto, M, Safont, M, Maurel, J, Ayuso, J, Aparicio, J, Feliu, J, Vera, R, Alonso, V, Gallego, J, Martin, M, Pericay, C, Ballesteros, E, Santos, J, Fernandez-Martos, C

Get full text

227 Predictive serum biomarkers in metastatic colorectal cancer patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (GEMCAD 09-01) by Pineda Losada, E, Salud, A, Vila-Navarro, E, Safont, M.J, Garcia-Giron, C, Aparicio, J, Vera, R, Escudero, M.P, Casado, E, Bosch, C, Bohn, U, Perez Carrion, R.M, Carmona Bayonas, A, Ayuso, J.R, Ripolles, T, Bouzas, R, Gironella, M, Garcia-Albeniz, X, Feliu, J, Maurel, J

Get full text

Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer by Morales, S., Velasco, A., Gasol, A., Córdoba, F., Vidal, J., Serrate, A., Valls, J., Samame, J.C., Gisbert, R., Moral, D., Llombart-Cussac, A., Salud, A., Matias-Guiu, X.

“…Circulating tumor cell (CTC) count and cytokeratin 19 (CK19) mRNA expression have a prognostic value for patients with metastatic breast cancer (MBC), but…”
Get full text